Erythropoeitin to facilitate stroke recovery: a randomised trial

King's College Hospital NHS Foundation Trust (UK)0 个研究点目标入组 90 人开始时间: 2012年11月27日最近更新: 2017年2月20日

适应症

试验速览

暂无简介。

•1. Supratentorial ischaemic stroke, confirmed on imaging
•2. Recruited within 48 hours of stroke onset. Time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when patient was last seen or was selfreported to be normal
•3. NIHSS score 624 with NIHSS 1A (level of consciousness) score <2 at the time of enrolment
•4. Reasonable expectation of availability to receive the full course of therapy, and to be available for subsequent follow-up visits
•5. Reasonable expectation that patient will receive standard poststroke physical, occupational and speech therapy as indicated

•1. Prestroke modified Rankin Score (mRS) >2
•2. Thrombolytic treatment with tPA following the index stroke
•3. Patients presenting with hemorrhagic and/or brain stem stroke
•4. Women who may be pregnant or breastfeeding
•5. Serum hemoglobin > 16 g/dL (males) or > 14 g/dL (females), or platelet count > 400,000/mm3
•6. Advanced liver, kidney, cardiac or pulmonary disease (serum bilirubin > 1.5 x upper limit of normal (ULN), Alkaline phosphatase > 2.5 x ULN, GGT>2.5xULN
•7. History of clotting disorders
•8. Expected survival < 1 year
•9. Allergy or other contraindication to erythropoeitin as per SPMC
•10. A known diagnosis of cancer (except nonmalignant skin cancer)
•11. A known diagnosis of epilepsy
•12. Uncontrolled hypertension (BP persistently > 220 mm Hg systolic or 120 mm Hg diastolic despite antihypertensive therapy)
•13. Preexisting and active major psychiatric or other chronic neurological disease
•14. Currently participating in another investigational study

发起方

King's College Hospital NHS Foundation Trust (UK)